A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MU... von O'Cearbhaill, R.E., Park, J.H., Halton, E.F., Diamonte, C.R., Mead, E., Lakhman, Y., Kane, P., Riviere, I.C., Brentjens, R.J.

Volltext